NVCT Nuvectis Pharma, Inc.

NASDAQ
$18.96

Nuvectis Pharma, Inc. (NVCT) is expected to report earnings on November 3, 2026, before the market open. The consensus earnings estimate is a loss of $0.22 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.6% since its last earnings release on August 4, 2026.

Nuvectis Pharma Missed Consensus Estimates
Tuesday, August 4, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 3
Tuesday · 7:30 AM ET
Earnings Whisper
-
vs ($0.22)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $19.43

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Nuvectis Pharma, Inc.

Nuvectis Pharma Inc. is a biopharmaceutical company. It focused on the development of innovative precision medicines for serious conditions of unmet medical need in oncology. Nuvectis Pharma Inc. is based in Fort Lee, NJ.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow